Compass Pathways plc
CMPSNext catalyst
CTX-009
Glioblastoma
Get an email about CMPS's next catalysts
Track Compass Pathways (CMPS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline
2 upcoming, 1 past
CTX-009 Phase 2 Est. Readout
Estimated primary completion for CTX-009 trial (NCT06548412) in Metastatic Biliary Tract Cancer. Topline data typically follows completion by weeks to months.
SourceCTX-009 Phase 3 Est. Readout
Estimated primary completion for CTX-009 trial (NCT05506943) in Biliary Tract Cancer. Topline data typically follows completion by weeks to months.
SourceHow CMPS's past catalysts played out
Market Overview
Stock performance and key metrics
Psilocybin
Treatment Resistant Depression
CTX-009
Glioblastoma
COMP360 psilocybin
PTSD - Post Traumatic Stress Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Psilocybin | Phase 3 | Treatment Resistant Depression | - | - |
CTX-009 | Phase 3 | Glioblastoma | - | - |
COMP360 psilocybin | Phase 3 | PTSD - Post Traumatic Stress Disorder | - | - |
Frequently asked questions
What is in Compass Pathways plc's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Compass Pathways plc's (CMPS) pipeline across Phase 3. Its lead program is CTX-009 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Compass Pathways plc's next FDA catalyst?→
Compass Pathways plc's (CMPS) next tracked catalyst is a Phase 2 readout expected May 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CMPS biotech catalysts?→
Add CMPS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Compass Pathways plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.